why choose us

First received: August 14, 2023

Clinical Trial: Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Renal Cell Carcinoma

Study Type: INTERVENTIONAL


Official Title: Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)

Brief Summary: The goal of this Clinical Study is to understand the outcomes by informing therapy choice for adjuvant treatment in clear cell renal cell carcinoma by using molecular residual disease.The main question[s] it aims to answer are:what is the progression free survival of a cohort of high risk resected RCC patients when treated based on MRDwhat is the overall survival of high risk resected RCC patients when treated based on MRDParticipants will forgo adjuvant therapy with pembrolizumab if they have no detectable…

Read more